Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 260.00 GBp
Change Today +4.25 / 1.66%
Volume 1.1K
SLN On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:35 AM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

silence therapeutics plc (SLN) Snapshot

Open
252.00 GBp
Previous Close
255.75 GBp
Day High
260.00 GBp
Day Low
252.00 GBp
52 Week High
06/1/15 - 335.00 GBp
52 Week Low
10/16/14 - 168.00 GBp
Market Cap
178.8M
Average Volume 10 Days
11.1K
EPS TTM
-0.22 GBp
Shares Outstanding
68.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SILENCE THERAPEUTICS PLC (SLN)

Related News

No related news articles were found.

silence therapeutics plc (SLN) Related Businessweek News

No Related Businessweek News Found

silence therapeutics plc (SLN) Details

Silence Therapeutics plc, a RNA technology company, engages in the development and delivery of RNA therapeutics. The company has an intellectual property portfolio, encompassing proprietary and in-licensed patents and patent applications, covering various aspects of its RNA based therapeutics. Its patented RNAi platform, AtuRNAi, is based on specific proprietary siRNA modules, stabilization technology, and other features. The company also has proprietary siRNA delivery technology platforms that comprise AtuPLEX, which delivers siRNA to the endothelial cells of the vascular system; and DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung. Its lead clinical product, Atu027, completed a Phase IIa study in pancreatic cancer. The company is also planning for Phase Ib study of Atu027 for the treatment of head and neck cancer. Its pre-clinical programs include Atu111 for the treatment of lung diseases; products for immunotherapy; Messenger RNA (mRNA) delivery, a method of introducing messenger RNA activity into the cell, in conditions where this is of therapeutic interest; and MicroRNA delivery that mediate natural cellular mechanisms, which exist to regulate gene expression. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

51 Employees
Last Reported Date: 04/27/15
Founded in 1994

silence therapeutics plc (SLN) Top Compensated Officers

Chief Executive (leave of absence) and Direct...
Total Annual Compensation: 200.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 167.0K GBP
Executive Director
Total Annual Compensation: 120.0K GBP
Compensation as of Fiscal Year 2014.

silence therapeutics plc (SLN) Key Developments

Silence Therapeutics plc Announces Interim Board Change

Silence Therapeutics plc announced that Ali Mortazavi, Chief Executive of Silence, has taken a temporary compassionate leave of absence for approximately two months from his role within the company due to an acute illness in his family. The company's Non-Executive Chairman, Dr. Alastair Riddell, will take on the role of Executive Chairman on an interim basis, until Ali Mortazavi's return. Alastair Riddell joined the Board of Silence in November 2013 and was appointed Non-Executive Chairman in January 2015. He has 32 years' experience in the biopharmaceutical sector, including 15 years as CEO and Chairman of several UK biotechs.

Silence Therapeutics plc Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 11:00 AM

Silence Therapeutics plc Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-13-2015 11:00 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.

Silence Therapeutics plc Announces Preliminary Analysis of its Phase 2A Trial of Atu027 in Pancreatic Cancer

Silence Therapeutics plc announced preliminary analysis of its Phase 2a trial of Atu027 in pancreatic cancer (Atu027-I-02). The positive results have led the Board to review its strategic use of resources in cancer, including the design and initiation of the proposed head and neck cancer study. The Company believes that the implication of higher and more frequent dosing warrants investigation prior to a full Phase 2 study in pancreatic cancer patients. As a result, the head and neck cancer study, as originally designed, has been deferred to enable the Company to explore this dosing issue further. Once the dosing regimen has been optimised in pancreatic cancer, other metastatic cancers like head and neck can be addressed. At this stage the Company will focus on achieving definitive success in pancreatic cancer, measured in terms of clear endpoints. A further statistical analysis of the pancreatic cancer study, which is expected to confirm the early indications of benefit of Atu027, will be made available in the company's AGM statement, which is due to be released on 1 June 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLN:LN 260.00 GBp +4.25

SLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arbutus Biopharma Corp $7.27 USD +0.27
Benitec Biopharma Ltd A$0.59 AUD +0.005
Dicerna Pharmaceuticals Inc $10.24 USD -0.28
Galena Biopharma Inc $1.49 USD 0.00
Regulus Therapeutics Inc $7.48 USD +0.28
View Industry Companies
 

Industry Analysis

SLN

Industry Average

Valuation SLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8,815.7x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11,799.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SILENCE THERAPEUTICS PLC, please visit www.silence-therapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.